1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Progression: new trials by email Literature Review of Progression trials Research Report on Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 |
Disease Progression (2) · Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1)
Ifosfamide (1) · camrelizumab (1) · famitinib (1)
Biomea Fusion Inc. (1) · Peking University People's Hospital (1)
China (1) · Greece (1) · Italy (1) · Netherlands (1) · Spain (1) · United States (1)
Steve Morris, MD (1) · Wei Guo, Ph.D. and M.D. (1)